GenVec said it will discontinue its Phase III trial of TNFerade in advanced pancreatic cancer patients after interim analysis did not provide enough persuasive evidence to continue.

Following the analysis, GenVec determined that the trial would not meet the goal of demonstrating sufficient clinical effectiveness in the population chosen for the trial to obtain regulatory approval.

The trial compared treatment with TNFerade in combination with standard of care to standard of care alone in subjects with locally advanced pancreatic cancer.

GenVEc is notifying the investigators and regulatory agencies of the discontinuation of the trial.